
 
 
 
 
 
 
 
 
 
 
   (1)  (1)200418849  拾、申請專利範圍  1 . 一種編碼埃坡黴素B羥化酶及其突變體與變異體之 經離析的核酸序列。  2 .如申請專利範圍第i項之經離析的核酸序列，.其包 括 SEQ ID NO ： 1，30，32，34，36，37，38，39，40， 41 ， 42 ， 60 ， 62 ， 64 ， 66 ， 68 ， 72 Μ 74 °  3 .如申請專利範圍第〗項之經離析的核酸序列，其包 括 SEQ ID NO : 1。  4.如申請專利範圍第1項之經離析的核酸序列，其編 碼在埃坡黴素B羥化酶酵素之活性部位中具有至少一個胺 基酸取代的突變體。  5 .如申請專利範圍第1項之經離析的核酸序列，其編  碼具有至少一個在 SEQ ID NO : 2之胺基酸 GLU3 1， ARG67，ARG88，ILE92，ALA93，VAL106，ILE130， ALA140 ， MET 176 ， PHE190 ， GLU23 1 ， SER294 ，  PHE23 7，或ILE3 6 5處的胺基酸取代之突變體。  6 .如申請專利範圍第1項之經離析的核酸序列，其編  碼具有至少一個在 SEQ ID NO : 2之胺基酸 LEU39, GLN43，ALA45, MET57，LEU58，HIS62，PHE63，SER64, SER65, ASP66, ARG67，GLN68, SER69，LEU74，MET75, VAL76, ALA77，ARG78，GLN79，ILE80，ASP84，LYS85, PR086，PHE87, ARG88，PR089, SER90，LEU91，ILE92, ALA93，MET94，ASP95，HIS99，ARG103, PHE110，ILE155, PHE169, GLN170, CYS172, SER173, SER174, ARG175,  -143 -  (2)  200418849  MET 1 76, LEU177, SERI 78, ARG1 79, ARG1 86,  LEU193, VAL23 3, GLY23 4, LEU23 5, AL A2 3 6,  LEU23 8, LEU23 9, LEU240, ILE241, AL A242,  HIS244， GLU24 5, THR246, THR247, ALA24 8,  MET2 5 0, LEU28 3, THR2 8 7, ILE2 8 8, AL A2 89,  THR29 1， AL A292, THR2 93, SER294, ARG29 5,  AL A297, THR298, GLU3 12, GLY3 1 3, VAL3 1 4,  GL Y3 1 6, VAL3 44, ALA3 4 5, PHE3 46, GLY3 47,  V AL3 5 0, HIS3 5 1 , GLN3 5 2, C YS 3 5 3， LEU3 54,  GLN3 5 6, LEU3 5 8, ALA3 5 9, GLU3 62, LYS3 8 9,  SER3 92, THR3 9 3, ILE394 和 TYR3 9 5處的胺基酸  變體。  7 .如申請專利範圍第1項之經離析的核酸序 碼包括 SEQ ID NO: 43，44，45，46，47，48 %  異體。  8 . —種由申請專利範圍第1項之經離析的核 編碼之多肽。  9. 一種經離析的核酸分子，其能夠在65°C 中1 6小時的雜交條件下雜交至申請專利範圍第 酸序列或該核酸序列的互補序列，該經離析的核 夠在在5 5 °C 0.5 X S S C中3 0分鐘的洗滌條件下 到該核酸序列或該核酸序列的互補序列。  10. —種包括SEQ ID NO : 2的經離析之多肽  11. 一種具有SEQ ID NO: 2的埃坡黴素B  PHE190, PHE23 7, GLY24 3, ASN249, GLU290, PHE296, VAL3 1 5, PHE3 4 8, GLY3 5 5, ASP391， 取代之突 列’其編 3 49之變 酸序列所 3X SSC 2項之核 酸分子能 保持雜交  羥化酶之  -144,  (3)  (3)200418849  經離析的突變多肽，其包括在具有SEQ ID NO : 2的埃玻 黴素B羥化酶酵素之活性部位中經至少一個胺基酸取代的 胺基酸序列。  12.—種具有SEQ ID NO : 2的埃坡黴素B羥化酶之 經離析的突變多肽，其編碼具有至少一個在SEQ ID NO : 2 之胺基酸 GLU31，ARG67，ARG88，ILE92，ALA93， VAL106 ， ILE130 ， ALA 140 ， MET 1 76 ， PHE1 90 ，  GLU231，SER294，PHE237，或 ILE3 6 5 處的胺基酸取代 之胺基酸序列。  13·—種具有SEQ ID NO ·· 2的埃坡黴素B羥化酶之  經離析的突變多肽，其編碼具有至少一個在SEQ ID NO :  2 之胺 基酸 LEU39， GLN43， ALA45, MET5 7, LEU58,  HIS62, PHE63, SER64, SER65, ASP66， ARG67, GLN68,  SER69, LEU74, MET75, VAL76, ALA77, ARG78, GLN79,  ILE80， ASP84， LYS85, PR086, PHE87, ARG88， PR089,  SER90, LEU91 , ILE92, ALA93, MET94, ASP95， HIS99,  ARG103, PHE 1 1 0, ILE155, PHE169, GLN1 70， C YS 1 72,  SER1 73， SER1 74, ARG1 75, MET 1 76, LEU1 77, SER1 78,  ARG1 79, ARG186, PHE 1 90, LEU193, VAL 2 3 3, GLY23 4,  LEU23 5, ALA23 6, PHE23 7, LEU23 8, LEU23 9, LEU240,  ILE241 , ALA242， GLY243, HIS244， GLU245, THR246,  THR247, AL A248, ASN249, MET2 5 0, LEU28 3, THR28 7,  ILE2 8 8, ALA2 8 9, GLU290, THR2915 AL A292， THR293 ,  SER294, ARG295, PHE296, ALA297, THR298, GLU3 12,  -145-  (4)  (4)200418849  GLY3 13, V AL3 1 4, VAL3 1 5, GLY3 1 6, VAL3 44, ALA3 4 5,  PHE3 46, GLY3 47, PHE3 4 8, VAL3 5 0, HIS351， GLN3 5 2,  CYS 3 5 3, LEU3 5 4, GLY3 5 5, GLN3 5 6, LEU3 5 8, ALA3 5 9,  GLU3 62, LYS 3 8 9， ASP3 91， SER3 92，THR3 9 3, ILE3 94 和  TYR3 95處的胺基酸取代之突變體。  14. 一 種包括 SEQ ID NO: 31，33，35，61，63，  6 5，6 7，6 9，7 1，7 3或7 5的埃坡黴素B羥化酶之經離析 的突變多肽。 φ  15. — 種包括 SEQ ID NO: 43，44，45，46，47，  48，或49的埃坡黴素B羥化酶之經離析的變異多肽。  1 6 . —種編碼鐵氧化還原蛋白之經離析的核酸序列。  1 7 .如申請專利範圍第1 6項之經離析的核酸序列，其 包括 SEQIDNO:3。  1 8 . —種由申請專利範圍第1 6項之經離析的核酸序列 所編碼之多肽。  19.一種經離析的核酸分子，其能夠在65°C 3X SSC ®  中1 6小時的雜交條件下雜交至SEQ ID NO : 3之核酸序 列或該SEQ ID NO : 3之核酸序列的互補序列，該經離析 的核酸分子能夠在5 5 °C 0.5 X S S C中3 0分鐘的洗滌條件 下保持雜交至SEQ ID NO: 3之核酸序列或該SEQ ID NO : 3之核酸序列的互補序列。  2 〇 . —種包括申請專利範圍第1項之經離析的核酸序 列之載體。  2 1 .如申請專利範圍第2 0項之載體，其進一步包括編  -146-  (5)  (5)200418849  碼鐵氧化還原蛋白之經離析的核酸序列。  22.—種包括如申請專利範圍第20項之載體的宿主細  胞。  2 3 . —種包括如申請專利範圍第2 1項之載體的宿主細  胞。  2 4 . —種製造重組微生物之方法，該微生物可羥基化 具有末端烷基的埃坡黴素以產生具有末端羥烷基的埃坡黴 素，該方法包括使用申請專利範圍第20或2 1項之載體以 轉染微生物。  2 5 . —種經重組產製的微生物，其可羥基化具有末端 烷基的埃坡黴素以產生具有末端羥烷基的埃坡黴素。  26. 如申請專利範圍第25項之經重組產製的微生物，  其中該微生物可表現具有SEQ ID NO : : 1，30，32，  34 ， 36 ， 37 ， 38 ， 39 ， 40 ， 41 ， 42 ， 60 ， 62 ， 64 ， 66 ，  6 8，7 2或7 4之核酸序列。  27. —種製造具有至少一種具有下述式I的埃坡黴素 之方法  HO-CH2-(Ai)n-(Q)m-(A2)〇.E (I) 其中  A i和A2爲獨立地選自包括下列的群組中：視需要經 取代的Ci-Cs-烷基和烯基；  Q爲視需要經取代的環系統，其包括1到3個環與在  -147-  200418849 (1) (1) 200418849 Scope of patent application 1. An isolated nucleic acid sequence encoding epothilone B hydroxylase and its mutants and variants. 2. The isolated nucleic acid sequence according to item i of the patent application scope, which includes SEQ ID NOs: 1, 30, 32, 34, 36, 37, 38, 39, 40, 41, 42, 60, 62, 64 , 66, 68, 72 M 74 ° 3. The isolated nucleic acid sequence according to the scope of the patent application, which includes SEQ ID NO: 1. 4. The isolated nucleic acid sequence according to item 1 of the patent application, which encodes a mutant having at least one amino acid substitution in the active site of the epothilone B hydroxylase enzyme. 5. The isolated nucleic acid sequence according to item 1 of the scope of patent application, which encodes at least one amino acid GLU3 1, SEQ ID NO: 2, ARG67, ARG88, ILE92, ALA93, VAL106, ILE130, ALA140, MET 176 , PHE190, GLU23 1, SER294, PHE23 7, or ILE3 6 5 mutants. 6. The isolated nucleic acid sequence according to item 1 of the scope of patent application, which encodes at least one amino acid LEU39, GLN43, ALA45, MET57, LEU58, HIS62, PHE63, SER64, SER65, ASP66 with SEQ ID NO: 2 , ARG67, GLN68, SER69, LEU74, MET75, VAL76, ALA77, ARG78, GLN79, ILE80, ASP84, LYS85, PR086, PHE87, ARG88, PR089, SER90, LEU91, ILE92, ALA93, MET94, ASP95, HIS99, ARG103, PHE110 , ILE155, PHE169, GLN170, CYS172, SER173, SER174, ARG175, -143-(2) 200418849 MET 1 76, LEU177, SERI 78, ARG1 79, ARG1 86, LEU193, VAL23 3, GLY23 4, LEU23 5, AL A2 3 6, LEU23 8, LEU23 9, LEU240, ILE241, AL A242, HIS244, GLU24 5, THR246, THR247, ALA24 8, MET2 5 0, LEU28 3, THR2 8 7, ILE2 8 8, AL A2 89, THR29 1, AL A292, THR2 93, SER294, ARG29 5, AL A297, THR298, GLU3 12, GLY3 1 3, VAL3 1 4, GL Y3 1 6, VAL3 44, ALA3 4 5, PHE3 46, GLY3 47, V AL3 5 0, HIS3 5 1, GLN3 5 2, C YS 3 5 3, LEU3 54, GLN3 5 6, LEU3 5 8, ALA3 5 9, GLU3 62, LYS3 8 9, SER3 92, THR3 9 3, ILE394 and TYR3 9 5 amine Acid variant. 7. The isolated nucleic acid sequence according to item 1 of the patent application scope includes SEQ ID NO: 43, 44, 45, 46, 47, 48% allosome. 8. A polypeptide encoded by the isolated core of the scope of patent application No. 1. 9. An isolated nucleic acid molecule capable of hybridizing to a patent application range of an acid sequence or a complementary sequence of the nucleic acid sequence under a hybridization condition at 65 ° C for 16 hours. C 0.5 XSSC to the nucleic acid sequence or the complementary sequence of the nucleic acid sequence under a 30-minute washing condition. 10. An isolated polypeptide comprising SEQ ID NO: 2 11. An epothilone B having SEQ ID NO: 2 PHE190, PHE23 7, GLY24 3, ASN249, GLU290, PHE296, VAL3 1 5, PHE3 4 8, GLY3 5 5, ASP391, the superseded nucleic acid molecule of item 3X SSC 2 of the acid-sequence sequence of its 3 49 can retain hybrid hydroxylase-144, (3) (3) 200418849 isolated mutation A polypeptide comprising an amino acid sequence substituted with at least one amino acid in the active site of an epothilone B hydroxylase enzyme having SEQ ID NO: 2. 12. An isolated mutant polypeptide having epothilone B hydroxylase of SEQ ID NO: 2, which encodes at least one amino acid GLU31, ARG67, ARG88, ILE92, ALA93 in SEQ ID NO: 2 , VAL106, ILE130, ALA 140, MET 1 76, PHE1 90, GLU231, SER294, PHE237, or ILE3 6 5 amino acid substituted amino acid sequence. 13 · —An isolated mutant polypeptide of epothilone B hydroxylase having SEQ ID NO ·· 2, which encodes at least one amino acid LEU39, GLN43, ALA45, MET5 having SEQ ID NO: 2 , LEU58, HIS62, PHE63, SER64, SER65, ASP66, ARG67, GLN68, SER69, LEU74, MET75, VAL76, ALA77, ARG78, GLN79, ILE80, ASP84, LYS85, PR086, PHE87, ARG88, PR089, SER90, LEU91, LEU91 , ALA93, MET94, ASP95, HIS99, ARG103, PHE 1 1 0, ILE155, PHE169, GLN1 70, C YS 1 72, SER1 73, SER1 74, ARG1 75, MET 1 76, LEU1 77, SER1 78, ARG1 79, ARG186, PHE 1 90, LEU193, VAL 2 3 3, GLY23 4, LEU23 5, ALA23 6, PHE23 7, LEU23 8, LEU23 9, LEU240, ILE241, ALA242, GLY243, HIS244, GLU245, THR246, THR247, AL A248, ASN249, MET2 5 0, LEU28 3, THR28 7, ILE2 8 8, ALA2 8 9, GLU290, THR2915 AL A292, THR293, SER294, ARG295, PHE296, ALA297, THR298, GLU3 12, -145- (4) (4) 200418849 GLY3 13, V AL3 1 4, VAL3 1 5, GLY3 1 6, VAL3 44, ALA3 4 5, PHE3 46, GLY3 47, PHE3 4 8, VAL3 5 0, HIS351, GLN3 5 2, CYS 3 5 3, LEU 3 5 4, GLY3 5 5, GLN3 5 6, LEU3 5 8, ALA3 5 9, GLU3 62, LYS 3 8 9, ASP3 91, SER3 92, THR3 9 3, ILE3 94 and TYR3 95 mutant. 14. An isolated mutant polypeptide comprising epothilone B hydroxylase comprising SEQ ID NO: 31, 33, 35, 61, 63, 6 5, 6, 7, 6, 9, 7, 1, 3 or 75 . φ 15. — An isolated mutant polypeptide of epothilone B hydroxylase including SEQ ID NO: 43, 44, 45, 46, 47, 48, or 49. 16. An isolated nucleic acid sequence encoding a ferredoxin. 17. The isolated nucleic acid sequence according to item 16 of the patent application, which includes SEQ ID NO: 3. 18. A polypeptide encoded by the isolated nucleic acid sequence in the 16th patent application. 19. An isolated nucleic acid molecule capable of hybridizing to a nucleic acid sequence of SEQ ID NO: 3 or a complementary sequence of the nucleic acid sequence of SEQ ID NO: 3 under hybridization conditions at 65 ° C 3X SSC® for 16 hours, The isolated nucleic acid molecule can maintain hybridization to the nucleic acid sequence of SEQ ID NO: 3 or the complementary sequence of the nucleic acid sequence of SEQ ID NO: 3 under washing conditions at 5 ° C 0.5 XSSC for 30 minutes. 2.. — A vector comprising the isolated nucleic acid sequence of the scope of patent application No. 1. 2 1. The vector of claim 20 in the scope of patent application, further comprising an isolated nucleic acid sequence of -146- (5) (5) 200418849 code iron redox protein. 22. A host cell comprising a vector such as the one claimed in claim 20. 2 3. A host cell comprising a vector such as the item 21 of the patent application. 2 4. A method for manufacturing a recombinant microorganism which can hydroxylate epothilone having a terminal alkyl group to produce epothilone having a terminal hydroxyalkyl group, and the method includes using patent application No. 20 or 2 1 The vectors are used to transfect microorganisms. 25. A recombinantly produced microorganism that can hydroxylate epothilone with a terminal alkyl group to produce epothilone with a terminal hydroxyalkyl group. 26. For example, a microorganism produced by recombination produced in the scope of application for a patent No. 25, wherein the microorganism can express SEQ ID NO :: 1, 30, 32, 34, 36, 37, 38, 39, 40, 41, 42, Nucleic acid sequences of 60, 62, 64, 66, 68, 72 or 74. 27. A method for producing at least one epothilone having the following formula I HO-CH2- (Ai) n- (Q) m- (A2) .E (I) wherein A i and A 2 are independent The ground is selected from the group consisting of Ci-Cs-alkyl and alkenyl, which are optionally substituted; Q is a ring system which is optionally substituted, which includes 1 to 3 rings and -147- 200418849 
 
 
 
 
 
 
 
 
 
 
   (6)  至少一個環中的至少一個碳對碳雙鍵；  η，m和〇爲選自包括下列的群組中之整數：〇和1， 且m或η或〇中至少有一者爲1，且 Ε爲一埃坡黴素核；  該方法包括將至少一種具有下面式11的埃坡黴素 CH3-(Ai)n.(Q)m-(A2)〇-E (II)  其中Ai，Q，A2，E，n，m和〇皆爲上面所定義者；  與一種能夠選擇性地催化該式II的羥基化之經重組 產製的微生物，或其所衍生的酵素接觸，及促成該羥基  化。  2 8 . —種製備式A埃坡黴素類似物之方法 (6) at least one carbon-to-carbon double bond in at least one ring; η, m and 0 are integers selected from the group consisting of: 0 and 1, and at least one of m or η or 〇 is 1, And E is an epothilone core; the method includes at least one epothilone CH3- (Ai) n. (Q) m- (A2) 〇-E (II) having the following formula 11 , A2, E, n, m and 0 are all defined above; contact with a recombinantly produced microorganism capable of selectively catalyzing the hydroxylation of the formula II, or an enzyme derived therefrom, and promote the hydroxyl group Into. 2 8. Method for preparing epothilone analogue of formula A 
 
 
 
 
 
 
 
 
 
 
   該方法包括經由與包括SEQ ID NO : 3 1的突變體埃坡黴 素B羥化酶酵素溫浸而將埃坡黴素B生物轉換成式a埃 坡黴素類似物。  2 9 . —種式A化合物  -148-  200418849 The method includes biologically converting epothilone B to an epothilone analog of formula a via warm dipping with a mutant epothilone B hydroxylase enzyme comprising SEQ ID NO: 31. 2 9. —A compound of formula A -148- 200418849 
 
 
 
 
 
 
 
 
 
 
   或其藥學上可接受的鹽。  3 〇 · —種埃坡黴素B羥化酶的同質模體，其在重疊於 附錄1中所列的構造座標所述對應的骨架原子之上時具有 小於約4.0 A的保守性殘基骨架原子根均方偏差。 Or a pharmaceutically acceptable salt thereof. 3 〇 — a homomorphic motif of an epothilone B hydroxylase, which has a conservative residue skeleton of less than about 4.0 A when superimposed on the corresponding skeleton atom described in the structural coordinates listed in Appendix 1. Atomic root mean square deviation. 
 
 
 
 
 
 
 
 
 
 
   3 1 . —種產生一相對於埃坡黴素B羥化酶具有變更的 生物學性質、功能、合意產物的產率、反應速率、受質特 異性、或活性之突變體的方法，該方法包括下列諸步驟： 鑑別出要突變的SEQ ID NO : 2所含一胺基酸；及突變該 經鑑別出的胺基酸以造出一突變體蛋白質。 31. A method for producing a mutant having altered biological properties, function, yield of a desired product, reaction rate, substrate specificity, or activity relative to epothilone B hydroxylase, the method The steps include: identifying an amino acid contained in SEQ ID NO: 2 to be mutated; and mutating the identified amino acid to create a mutant protein. 
 
 
 
 
 
 
 
 
 
 
   3 2.如申請專利範圍第3 1項之方法，其中係使用在重 疊於附錄1中所列構造座標所述對應的骨架原子之上時具 有小於約4.0 A的保守性殘基骨架原子根均方偏差之埃坡 黴素B羥化酶的同質性模型來鑑別出要突變的 SEQ ID NO : 2所含一胺基酸。  3 3 .如申請專利範圍第3 1項之方法，其中該經鑑別出  之胺基酸爲 SEQ ID NO :2的 LEU39, GLN43, ALA45,  MET5 7, LEU58, HIS62， PHE63, SER64, SER65, ASP66,  ARG67, GLN68 , SER69， LEU74, MET75, VAL76, ALA77,  ARG78, GLN79, ILE80， ASP84, LYS85, PR086, PHE87,  ARG88, PR089, SER90, LEU91， ILE92, ALA93， MET94,  稱 ASP95， HIS99, ARG103， PHE110， ILE155， PHE169,  -149-  (8)  200418849  GLN 1 70, C YS 1 72， SER173， SER1 74, ARG1 75, MET 1 76,  LEU 1 77, SER178, ARG1 79， ARG1 86, PHE 1 90, LEU193,  VAL 2 3 3, GLY23 4, LEU23 5， ALA2 3 6, PHE2 3 7, LEU2 3 8,  LEU23 9, LEU240， ILE241， ALA242, GLY243， HIS244,  GLU24 5, THR246， THR247, ALA248, ASN249, MET2 5 0,  LEU283, THR287， ILE28 8， ALA289, GLU290, THR29 1,  AL A292, THR293, SER294, ARG295, PHE296, ALA297,  THR298, GLU3 12, GLY3 13， VAL3 14, VAL3 15, GLY3 1 6,  VAL344, AL A3 4 5， PHE3 46， GLY3 47, PHE3 4 8, VAL 3 5 0,  HIS3 5 1， GLN3 5 2， CYS 3 5 3， LEU3 54， GLY 3 5 5, GLN3 5 6,  LEU3 5 8, AL A3 5 9， GLU3 62, LYS 3 89, ASP391， SER3 92,  THR3 93, ILE394 和 TYR3 9 5。     3 4 .如申請專利範圍第3 1 項之方法 ，其中該經鑑別出  之胺基酸爲SEQ ID | NO : 2 的 GLU3 1， ARG67， ARG88，  ILE92，ALA93，VAL106，ILE130，ALA140，MET176， PHE190，GLU23 1，SER294，PHE23 7，或 ILE3 65。  3 5 .如申請專利範圍第31項之方法，其中相對於使用 埃坡黴素B羥化酶所得合意產物的產率該突變蛋白質可改 良合意產物的產率。  3 6 .如申請專利範圍第3 5項之方法，其中該合意產物 爲埃坡黴素F。  3 7 .如申請專利範圍第31項之方法，其中相對於使用 埃坡黴素B羥化酶所得反應速率該突變體可改良反應速 率 〇  -150-  200418849  Ο)  3 8 .如申請專利範圍第3 1項之方法，其中相對於埃坡 黴素B羥化酶的受質特異性該突變體展現出變更的受質特 異性。  3 9 .如申請專利範圍第3 8項之方法，其中係胺基酉爱 SER294受到突變。  4 0 .如申請專利範圍第3 1項之方法，其中該突變體展 現出基本上類似於埃坡黴素B羥化酶的的生物學活性或％ 能。  4 1 · 一種機械可讀取型數據貯存介質，其包括由附錄1 所列出的構造座標所編碼的數據貯存資料。  -151 - 3 2. The method according to item 31 of the scope of patent application, wherein the roots of skeleton atoms with conservative residues of less than about 4.0 A are superimposed on the corresponding skeleton atoms described in the structural coordinates listed in Appendix 1. The homogeneity model of epothilone B hydroxylase with a square deviation to identify the amino acid contained in SEQ ID NO: 2 to be mutated. 3 3. The method according to item 31 of the scope of patent application, wherein the identified amino acid is LEU39, GLN43, ALA45, MET5 7, LEU58, HIS62, PHE63, SER64, SER65, ASP66 of SEQ ID NO: 2 , ARG67, GLN68, SER69, LEU74, MET75, VAL76, ALA77, ARG78, GLN79, ILE80, ASP84, LYS85, PR086, PHE87, ARG88, PR089, SER90, LEU91, ILE92, ALA93, MET94, called ASP95, HIS99, ARG PHE110, ILE155, PHE169, -149- (8) 200418849 GLN 1 70, C YS 1 72, SER173, SER1 74, ARG1 75, MET 1 76, LEU 1 77, SER178, ARG1 79, ARG1 86, PHE 1 90, LEU193, VAL 2 3 3, GLY23 4, LEU23 5, ALA2 3 6, PHE2 3 7, LEU2 3 8, LEU23 9, LEU240, ILE241, ALA242, GLY243, HIS244, GLU24 5, THR246, THR247, ALA248, ASN249, MET2 5 0, LEU283, THR287, ILE28 8, ALA289, GLU290, THR29 1, AL A292, THR293, SER294, ARG295, PHE296, ALA297, THR298, GLU3 12, GLY3 13, VAL3 14, VAL3 15, GLY3 1 6, VAL344, AL A3 4 5, PHE3 46, GLY3 47, PHE3 4 8, VAL 3 5 0, HIS3 5 1, GLN3 5 2, CYS 3 5 3, LEU3 54, GLY 3 5 5, GLN3 5 6, LEU3 5 8, AL A3 5 9, GLU3 62, LYS 3 89, ASP391, SER3 92, THR3 93, ILE394 and TYR3 9 5. 3 4. The method according to item 31 of the scope of patent application, wherein the identified amino acid is GLU3 1, SEQ ID | NO: 2, ARG67, ARG88, ILE92, ALA93, VAL106, ILE130, ALA140, MET176, PHE190, GLU23 1, SER294, PHE23 7, or ILE3 65. 35. The method of claim 31, wherein the mutant protein can improve the yield of the desired product relative to the yield of the desired product using epothilone B hydroxylase. 36. The method of claim 35, wherein the desired product is epothilone F. 37. The method according to item 31 of the scope of patent application, wherein the mutant can improve the reaction rate with respect to the reaction rate obtained by using epothilone B hydroxylase 0-150-200418849 0) 3 8 The method of item 31, wherein the mutant exhibits an altered receptor specificity with respect to the receptor specificity of epothilone B hydroxylase. 39. The method according to item 38 of the scope of patent application, wherein the amino group SER294 is mutated. 40. The method of claim 31, wherein the mutant exhibits a biological activity or% energy that is substantially similar to epothilone B hydroxylase. 4 1 · A mechanically readable data storage medium that includes data storage data encoded by structural coordinates listed in Appendix 1. -151- 
 
 
 
 
 
 
 
 
 
 
 
